Literature DB >> 18752381

Reduction in adverse symptoms as blood pressure becomes controlled.

Cynthia A Weber1, Megan R Leloux, Barry L Carter, Karen B Farris, Yinghui Xu.   

Abstract

STUDY
OBJECTIVES: To evaluate trends in adverse symptoms as blood pressure becomes controlled, and to determine if these symptoms are influenced by social support and self-efficacy.
DESIGN: Secondary analysis from a randomized controlled study of physician-pharmacist collaboration to improve blood pressure control.
SETTING: Five university-affiliated primary care clinics. PATIENTS: A total of 179 patients (aged 21-85 yrs) with uncontrolled primary hypertension who were taking no antihypertensive drugs or up to three antihypertensive drugs at baseline were randomized to the intervention group, in which pharmacists were involved in their care, or to the control group, who received usual care from their physicians. Of these patients, 160 completed the study: 92 were in the intervention group, and 68 were in the control group. INTERVENTION: In both groups, patient-reported symptoms suggestive of adverse drug reactions (ADRs) were recorded at each study visit with use of a structured ADR questionnaire. Social support and self-efficacy questionnaires were also administered at each study visit.
MEASUREMENTS AND MAIN RESULTS: Patients' ADR scores decreased significantly from baseline to the end of the study in both the control (from a mean of 26.5 to 18.4) and intervention (from 29.9 to 22.7) groups (p<0.0001 for both comparisons), although no significant difference was noted between groups. The mean +/- SD number of antihypertensive drugs/patient increased in both the intervention (from 1.5 +/- 1.0 to 2.4 +/- 0.9 drugs) and control (from 1.4 +/- 1.0 to 1.9 +/- 1.0 drugs) groups; however, the difference between groups was significant only at the end of the study. Additional analyses were performed on self-efficacy and social support to determine a potential reason for the reduction in ADR scores despite an increase in drug use. Improvements in self-efficacy and social support scores were significantly and independently associated with improvement in ADR score (p<0.05).
CONCLUSIONS: In both groups, ADR scores improved despite an increase in antihypertensive drug use. Improvements in social support and, to a lesser extent, self-efficacy were associated with improvements in ADR scores. Patients should not expect an increase in distressful symptoms as their blood pressure becomes controlled with antihypertensive drugs, especially when adequate social support is available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752381      PMCID: PMC2768032          DOI: 10.1592/phco.28.9.1104

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  32 in total

1.  Discontinuation of antihypertensive drugs due to adverse events: a systematic review and meta-analysis.

Authors:  S D Ross; K S Akhras; S Zhang; M Rozinsky; L Nalysnyk
Journal:  Pharmacotherapy       Date:  2001-08       Impact factor: 4.705

2.  Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.

Authors:  N K Hollenberg; G H Williams; R Anderson
Journal:  Arch Intern Med       Date:  2000-05-22

3.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

4.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  Long-term persistence with antihypertensive drugs in new patients.

Authors:  E Degli Esposti; A Sturani; M Di Martino; P Falasca; M V Novi; G Baio; S Buda; M Volpe
Journal:  J Hum Hypertens       Date:  2002-06       Impact factor: 3.012

6.  A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy.

Authors:  Luca Degli Esposti; Ezio Degli Esposti; Giorgia Valpiani; Mirko Di Martino; Stefania Saragoni; Stefano Buda; Gianluca Baio; Alessandro Capone; Alessandra Sturani
Journal:  Clin Ther       Date:  2002-08       Impact factor: 3.393

7.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

8.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

9.  Relationship between symptoms and health-related quality of life in patients treated for hypertension.

Authors:  Steven R Erickson; Brent C Williams; Larry D Gruppen
Journal:  Pharmacotherapy       Date:  2004-03       Impact factor: 4.705

10.  A cluster randomized trial to evaluate physician/pharmacist collaboration to improve blood pressure control.

Authors:  Barry L Carter; George R Bergus; Jeffrey D Dawson; Karen B Farris; William R Doucette; Elizabeth A Chrischilles; Arthur J Hartz
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-04       Impact factor: 3.738

View more
  6 in total

1.  Pharmacist-physician comanagement of hypertension and reduction in 24-hour ambulatory blood pressures.

Authors:  Cynthia A Weber; Michael E Ernst; Genesis S Sezate; Shimin Zheng; Barry L Carter
Journal:  Arch Intern Med       Date:  2010-10-11

2.  Effect of self-efficacy and social support on adherence to antihypertensive drugs.

Authors:  Thomas J Criswell; Cynthia A Weber; Yinghui Xu; Barry L Carter
Journal:  Pharmacotherapy       Date:  2010-05       Impact factor: 4.705

3.  Physician and pharmacist collaboration to improve blood pressure control.

Authors:  Barry L Carter; Gail Ardery; Jeffrey D Dawson; Paul A James; George R Bergus; William R Doucette; Elizabeth A Chrischilles; Carrie L Franciscus; Yinghui Xu
Journal:  Arch Intern Med       Date:  2009-11-23

4.  Similar blood pressure values across racial and economic groups: baseline data from a group randomized clinical trial.

Authors:  Barry L Carter; Christopher S Coffey; Liz Uribe; Paul A James; Brent M Egan; Gail Ardery; Elizabeth A Chrischilles; Dixie Ecklund; Mark Vander Weg; Thomas Vaughn
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-04-01       Impact factor: 3.738

Review 5.  Avoiding Pitfalls With Implementation of Randomized Controlled Multicenter Trials: Strategies to Achieve Milestones.

Authors:  Barry L Carter; Gail Ardery
Journal:  J Am Heart Assoc       Date:  2016-12-19       Impact factor: 5.501

6.  A De Novo Pharmacist-Family Physician Collaboration Model in a Family Medicine Clinic in Alberta, Canada.

Authors:  Hoan Linh Banh; Andrew J Cave
Journal:  Pharmacy (Basel)       Date:  2021-05-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.